Granite Point Capital Management, L.P. Xilio Therapeutics, Inc. Transaction History
Granite Point Capital Management, L.P.
- $0
- Q3 2023
Shares
2 transactions
Others Institutions Holding XLO
# of Institutions
33Shares Held
12.6MCall Options Held
0Put Options Held
0-
Bain Capital Life Sciences Investors, LLC Boston, MA3.79MShares$2.95 Million0.74% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD3MShares$2.34 Million0.09% of portfolio
-
River Vest Venture Management LLC St. Louis, MO1.44MShares$1.12 Million20.01% of portfolio
-
Morgan Stanley New York, NY1.11MShares$867,9370.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA903KShares$703,9740.0% of portfolio
About Xilio Therapeutics, Inc.
- Ticker XLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,471,600
- Market Cap $21.4M
- Description
- Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...